1-9 of 9
John Taper
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Clinical Trials & Observations
Sun Loo, Andrew W. Roberts, Natasha S. Anstee, Glen A. Kennedy, Simon He, Anthony P. Schwarer, Anoop K. Enjeti, James D’Rozario, Paula Marlton, Ian A. Bilmon, John Taper, Gavin Cull, Campbell Tiley, Emma Verner, Uwe Hahn, Devendra K. Hiwase, Harry J. Iland, Nick Murphy, Sundra Ramanathan, John Reynolds, Doen Ming Ong, Ing Soo Tiong, Meaghan Wall, Michael Murray, Tristan Rawling, Joanna Leadbetter, Leesa Rowley, Maya Latimer, Sam Yuen, Stephen B. Ting, Chun Yew Fong, Kirk Morris, Ashish Bajel, John F. Seymour, Mark J. Levis, Andrew H. Wei
Journal: Blood
Blood (2023) 142 (23): 1960–1971.
https://doi.org/10.1182/blood.2023020301
Published: 2023
Includes: Supplemental data
Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Andrew H Wei, MBBS, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Kirk L Morris, MBBA, FRACP, FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Simon He, MBBS, FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Stephen B Ting, MBBS, FRACP, FRCPA, PhD, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, Sam Yuen, MBBS, FRACP, FRCPA, James D'Rozario, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, John Taper, MBBS, FRACP, FRCPA, B Pharm, Gavin Cull, MBBS, MD FRACP, FRCPA, Campbell Tiley, MBBS, FRACP, FRCPA, Emma Verner, MBBS, FRACP, FRCPA, Uwe H Hahn, MBBS, MD FRCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Harry Iland, MBBS, FRACP, FRCPA, MHGSA, Nichloas Murphy, MBBS, FRACP, FRCPA, Sundra Ravanathan, MBBS, FRACP, FRCPA, RCPA, Uyen Nguyen, Doen Ming Ong, MBBS, FRACP, FRCPA, RCPA, Sun Loo, MBBS, FRACP, FRCPA, RCPA, Ing-Soo Tiong, MBBS, FRACP, FRCPA, RCPA, Meaghan Wall, MBBS, FRACP, FRCPA, RCPA, PhD, Natasha S Anstee, PhD, Mark Levis, MD PhD, Michael Murray, PhD DSc, Tristan Rawling, PhD, Joanna Leadbetter, PhD, Ashish Bajel, FRACP, Andrew W Roberts, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-137334
Published: 2020
Journal Articles

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Peter Tan, James D'Rozario, John Taper, MBBS FRACP FRCPA, Anthony Richard Powell, FRACP, MBBS, Ian Irving, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Susan Branford, PhD FFSc (RCPA), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Luke Anderson, Othon L Gervasio, Timothy P. Hughes, MD
Journal: Blood
Blood (2016) 128 (22): 5447.
https://doi.org/10.1182/blood.V128.22.5447.5447
Published: 2016
Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD FFSc (RCPA), Susan Branford, PhD, Tracey Gerber, Belinda Butcher, BSc MBiostat PhDCMPP, Samar Issa, MBBS FRACP FRCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Mark S Hertzberg, MBBS PhDFRACP FRCPA, David Gottlieb, MBBS MDFRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Robin Filshie, PhDFRACP FRCPA, Christopher Arthur, MD, Yiu-Lam Kwan, MBBS, FRACP, FRCPA, Cecily Forsyth, MBBS, FRACP, FRCPA, John Taper, MBBS FRACP FRCPA, David M. Ross, MBBS, PhD FRACP, FRCPA, Constantine S. Tam, MBBS, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Timothy P. Hughes, MD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2016) 128 (22): 939.
https://doi.org/10.1182/blood.V128.22.939.939
Published: 2016
Journal Articles

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Bradstock Kenneth, Emma Link, DPhil, Juliana Di Iulio, BAppSc, PhD, Jeff Szer, MB, BS, FRACP, Paula Marlton, MBBS, FRCPA, FRACP, Andrew Wei, MBBS, PhD, Arno Enno, MB,BS,FRCPA, FRACP, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Ian D. Lewis, MBBS PhDFRACP FRCPA, James D'Rozario, MB BS FRACP, Luke Coyle, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Philip Campbell, MB ChB FRACP FRCPA, Michael Francis Leahy, FRACP, Uwe H Hahn, MDFGCP FRCPA, Paul Cannell, MD, Campbell Tiley, MBBS,FRACP, FRCPA, Raymond M. Lowenthal, MD FRACP, FRCP, John Moore, MBBS, MD FRACP , FRCPA, Kimberly Cartwright, FRACP,MDFRCPA, Ilona Cunningham, John Taper, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Andrew W. Roberts, MBBS PhD, Warwick John Benson, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Sandra F. Deveridge, MDBSc,FRACP,FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K. Mills, MBBS, FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Peter G Bardy, MBBS, FRACP, FRCPA, Lynda Campbell, John F. Seymour, MD
Journal: Blood
Blood (2016) 128 (22): 338.
https://doi.org/10.1182/blood.V128.22.338.338
Published: 2016
Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Mark S Hertzberg, MBBS PhDFRACP FRCPA, Maher K Gandhi, PhDFRACP FRCPath FRCP, Belinda Butcher, BSc MBiostat PhDCMPP, Ruth Columbus, BSc PhD, John Taper, MBBS FRACP FRCPA, Judith Trotman, MBChB, Devinder Gill, MB FRCPath FRACP FRCPA, Shir-Jing Ho, MBBS FRACP FRCPA, Keith Fay, MBChB FRACP FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Andrew P Grigg, MBBS MD, Geoff Chong, MBBS FRACP, Ian D. Lewis, MBBS PhDFRACP FRCPA, Sam Milliken, MBBS FRACP FRCPA, William Renwick, Uwe Hahn, MBBS FRACP FRCPA, Robin Filshie, PhDFRACP FRCPA, Anne-Marie Watson, MBBS FRACP FRCPA, George Kannourakis, MD PhD, Max Wolf, MBBS FRACP FRCPA, Andrew Wirth, MBBS, Pauline Therese Warburton, MBBS PhDFRACP FRCPA, Stephen Robert Larsen, MBBS PhDFRCPA FRACP, John F. Seymour, MBBS, PhD, Rodney Hicks, MBBS FRACP
Journal: Blood
Blood (2015) 126 (23): 815.
https://doi.org/10.1182/blood.V126.23.815.815
Published: 2015
Journal Articles

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

Clinical Trials & Observations
David T. Yeung, Michael P. Osborn, Deborah L. White, Susan Branford, Jodi Braley, Alan Herschtal, Michael Kornhauser, Samar Issa, Devendra K. Hiwase, Mark Hertzberg, Anthony P. Schwarer, Robin Filshie, Christopher K. Arthur, Yiu Lam Kwan, Judith Trotman, Cecily J. Forsyth, John Taper, David M. Ross, Jennifer Beresford, Constantine Tam, Anthony K. Mills, Andrew P. Grigg, Timothy P. Hughes
Journal: Blood
Blood (2015) 125 (6): 915–923.
https://doi.org/10.1182/blood-2014-07-590315
Published: 2015
Includes: Supplemental data
Journal Articles

All- trans -retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

CME
Harry J. Iland, Ken Bradstock, Shane G. Supple, Alberto Catalano, Marnie Collins, Mark Hertzberg, Peter Browett, Andrew Grigg, Frank Firkin, Amanda Hugman, John Reynolds, Juliana Di Iulio, Campbell Tiley, Kerry Taylor, Robin Filshie, Michael Seldon, John Taper, Jeff Szer, John Moore, John Bashford, John F. Seymour
Journal: Blood
Blood (2012) 120 (8): 1570–1580.
https://doi.org/10.1182/blood-2012-02-410746
Published: 2012
Journal Articles

Early Dose-Escalation in Chronic Myeloid Leukaemia Patients with Low Plasma Imatinib Levels Leads to Equivalent BCR-ABL Values and Drug Levels at 6 Months to Those with Optimal Drug Levels: First Analysis From the TIDEL II Trial of De-Novo Patients Treated with 600mg Imatinib.

Michael P Osborn, Deborah L White, PhD, Verity A Saunders, Bronwyn Cambareri, Susan Branford, PhD, Andrew Menelaou, Bereha Khodr, PhD, Cassandra Slader, Mark Hertzberg, Anthony Schwarer, David Ma, MD, Christopher Arthur, Cecily J. Forsyth, Samar Issa, Yiu Lam Kwan, John Taper, Andrew Grigg, Timothy P. Hughes, MD
Journal: Blood
Blood (2009) 114 (22): 1131.
https://doi.org/10.1182/blood.V114.22.1131.1131
Published: 2009